Compare FMC Corp (FMC) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FMC Corp vs IDEXX Laboratories, Inc. — how do they compare? FMC Corp trades at $8.28 (market cap $1.39B), while IDEXX Laboratories, Inc. trades at $519.87 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is far larger — about 29.1× FMC Corp's market cap, and FMC Corp pays a 3.59% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold FMC Corp for 68 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| FMC | IDXX | |
|---|---|---|
Market Cap | $1.39B | $40.43B |
Volume | 4,145,979 | 692,164 |
Sector | Basic Materials | Health |
52-Week High | $30.63 | $766.68 |
52-Week Low | $8.44 | $504.70 |
Typical Hold Time | 68 Days | 46 Days |
Enterprise Value | $5.19B | $41.32B |
Dividend Yield | 3.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FMC trades at $8.36, down 8.03% in the past 24 hours, reflecting bearish technical signals and weak profitability. The company reported a net loss of -$2.24B in 2025, with negative margins and declining revenue. Recent news includes a regulatory filing for rimisoxafen in Brazil and a minority equity investment by Tessenderlo Group. Cash flow trends show volatility, with 2025 net cash flow positive at $227M but driven by financing activities.
The outlook remains challenging due to persistent losses and high debt, though analyst consensus suggests upside with a $14.60 price target. Key risks include execution on deleveraging, cyclical industry pressures, and competitive threats. Investment opportunity hinges on successful turnaround efforts and new product approvals.
IDEXX Laboratories (IDXX) trades at $517.47, up 2.13% with strong earnings momentum after beating Q2 2026 estimates. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and expanded diagnostic platforms highlight growth initiatives, while analyst consensus remains bullish with a $665 price target representing 28.5% upside potential.
The outlook remains positive given consistent earnings beats and expanding veterinary diagnostics market share. Key risks include FX headwinds, weaker U.S. vet visits, and premium valuations at 36x P/E. Institutional ownership trends show mixed activity with recent insider selling, but long-term growth drivers in pet healthcare innovation support the bullish analyst stance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About FMC Corp
FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
